Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sigachi Industries Limited (SIGACHI.NS)
INR24.05
+0.47 (+1.99%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Kalyan’s Tulsi Ram Chambers 500049
Hyderabad, IN
Hyderabad, IN
CEO
Amit Raj Sinha
Website
sigachi.com
IPO
2021-11-15
ISIN INE0D0K01022
Also trades on
Bombay Stock Exchange · SIGACHI.BO (INR)
National Stock Exchange of India · SIGACHI.NS (INR)
Description
Sigachi Industries Limited, based in Hyderabad, India, specializes in the production and global distribution of microcrystalline cellulose and cellulose powder. Founded in 1989, the company supplies these essential materials to a diverse clientele across various sectors, including the pharmaceutical, nutraceutical, food and nutrition, cosmetic, and chemical industries, both within India and through exports.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR24.05
+0.47 (+1.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.46
Float Shares
159.36M
Free Float %
41.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.66% | +3.81% | +5.20% | +5.25% | -44.36% | -31.72% | -60.35% | -10.90% | -64.49% | -64.49% | -64.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
24.05
Quality scores
Altman Z-Score
2.01
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.1% Q1'26: -4.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-203.9% Q1'26: -37.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.9% ★ Q1'26: -59.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.6% Q1'26: +9.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.4% Q1'26: +7.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-7.0% ★ Q1'26: -6.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.02× Q1'26: 2.47× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|
| Revenue |
3.02B
est: 2.71B (+11.4%)
|
3.99B
est: 3.42B (+16.7%)
|
4.88B
est: 3.42B (+42.8%)
|
| EBITDA |
653.97M
est: 606.74M (+7.8%)
|
858.35M
est: 926.78M (-7.4%)
|
1.21B
est: 926.78M (+30.0%)
|
| EBIT |
587.71M
est: 549.86M (+6.9%)
|
750.35M
est: 693.46M (+8.2%)
|
1.05B
est: 693.46M (+51.0%)
|
| Net Income |
435.36M
est: 542.03M (-19.7%)
|
571.80M
est: 661.11M (-13.5%)
|
695.63M
est: 615.10M (+13.1%)
|
| SGA |
396.49M
est: 322.30M (+23.0%)
|
366.08M
est: 406.47M (-9.9%)
|
925.07M
est: 406.47M (+127.6%)
|
| EPS |
1.42
est: 1.32 (+7.6%)
|
1.81
est: 1.61 (+12.4%)
|
2.06
est: 1.61 (+28.0%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
507.81M
OE per share TTM
1.27
Owner's Yield
6.19%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
54.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 37.0K | 0.65% |
| 2 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 892.0K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
364.9K
Shares Outstanding
382.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amit Raj Sinha | Chief Executive Officer, MD & Director | 26M | male |
| Rabindra Prasad Sinha | Executive Chairman | 17M | male |
| Chidambarnathan Shanmuganathan | Executive Vice Chairman | 17M | male |
| Lijo Stephen Chacko | Deputy Group Chief Executive Officer | 60.0K | male |
| Bobby Agrawal | Vice President & Business Head | — | male |
| Vivek Kumar | Company Secretary & Compliance Officer | — | male |
| Subbarami Reddy Oruganti | Chief Financial Officer | — | male |
| Subramanian Ananthanarayanan | Senior Vice President of HR | — | male |
| C. Bhavani Shanmugam | Director of Sigachi U.S. Inc | — | male |
| Radhakrishna Dattatraya Gadakh | Vice President Operations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIGACHI.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
